Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NMRA

+ Watchlist+ Portfolio

Neumora Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.37
52-Week Range
$0.30 – $3.65
Market Cap
$65.48M
P/E (TTM)
—
EPS (TTM)
-1.06
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.54
PEG Ratio
—
Return on Equity
-252.71%
Return on Assets
-85.63%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
4.08
Debt/Equity
2.89
Total Debt
$53.57M
Free Cash Flow
$-97.67M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$33.39M

Market Snapshot

About

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain diseases. The company uses precision medicine approaches and biomarker-driven strategies to address neuropsychiatric and neurodegenerative disorders.